Phase 4 N=46 Pilot Study: Preoperative Nicotine Lozenges
Smoking
Primary: Exhaled Carbon Monoxide Concentration — 8.3; 12.7 Parts per million — p=0.12
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=111 Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 9.1; 7.1 months
N/A N=377 Coping Intervention After Embryo Transfer
Anxiety · Depression
Primary: Anxiety — 6.279; 6.223; 6.095; 7.302 units on a scale — p=<0.05
Phase 2 N=48 Effects of CLA Supplements on Body Weight and Fat Oxidation
Obesity
Primary: Fat Mass — -1.0; 0.7 kg — p=<0.05
N/A N=24 Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes
Partially Edentulous Mandible · Type 2 Diabetes
Primary: Implant Stability Quotient (ISQ) — 61.9; 61.3 units on a scale
Phase 2 N=153 Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
HIV Infections
Primary: Percentage of Participants With Grade 3 or 4 Adverse Events (AEs) — 20.3; 25; 15.4; 30 percentage of participants
Phase 2 N=58 Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 27 participants
Phase 1 N=40 Pharmacokinetics of BAF312 in Patients With Hepatic Impairment
Hepatic Impairment
Primary: Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) — 68.3; 53.9; 73.7…
Phase 2 N=119 High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Renal Cancer · Kidney Cancer
Primary: Progression-free Survival — 6.0; 5.7 months
N/A N=119 Exercise and Inflammation in the Elderly
Inflammation · Insulin Sensitivity
Primary: Insulin Sensitivity — 50.2; 40.7; 57.5; 42.3 μmol/kgFFM/min
Phase 4 N=16 PharmacofMRI of Anxiolytic Medications (Pregabalin)
Anxiety Disorders
Primary: Effect of Pregabalin (Two Doses) Versus Placebo — 0.6; -0.1; 0.6 % signal change L amygdala + anticipn
N/A N=10 Levels of Raltegravir in the Female Genital Tissue
HIV
Primary: Tissue Raltegravir Concentrations — 117 ng/mL
Phase 1 N=48 A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.
Kidney Failure, Chronic Therapy; Hemodialysis
Primary: Pharmacokinetics of Iron From Soluble Ferric Pyrophosphate: Cohorts 1, 2, 3, 6 (Mean Total Serum Iron, Baseline Corrected) — 18.87125; 14.625; 20.13333; 14.806…
N/A N=759 Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice
Kidney Insufficiency · Secondary Hyperparathyroidism
Primary: Percentage of Participants Who Achieved Intact Parathyroid Hormone (iPTH) Levels Within the Target Range After 12 Months — 30.4; 30.5; 70.2 percentage of participants
Phase 2 N=24 Etanercept and Vascular Function in Psoriasis
PSORIASIS
Primary: Vascular Function as Measured by Brachial Artery Flow-mediated Dilation (FMD) — 9.71; 11.15 percentage of brachial artery diameter